Lau C L, Palmer S M, D'Amico T A, Tapson V F, Davis R D
Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Clin Transpl. 1998:327-40.
Lung transplantation is a viable therapy for patients with a variety of end-stage lung diseases. Our active program now includes over 200 lung transplant operations with acceptable one- and 3-year survival rates of 78% and 61%. A major focus of clinical research at this institution is to design strategies to prevent the development of chronic allograft dysfunction. Our preliminary work in this regard has been encouraging. In addition, a major research focus has been to design protocols to prevent the development of posttransplant infections. Our work with aerosolized ABLC represents a major advance at our center, and additional randomized prospective studies are ongoing to define the optimal antifungal prophylaxis after transplantation. Ongoing clinical and basic research at Duke and elsewhere should continue to advance the field of clinical transplantation and ultimately lead to more acceptable long-term outcomes for lung allograft recipients.
肺移植对于患有各种终末期肺病的患者来说是一种可行的治疗方法。我们积极开展的项目目前已包括200多例肺移植手术，1年和3年生存率分别为78%和61%，令人满意。该机构临床研究的一个主要重点是设计预防慢性移植物功能障碍发生的策略。我们在这方面的初步工作令人鼓舞。此外，一个主要的研究重点是设计预防移植后感染发生的方案。我们使用雾化两性霉素B脂质体复合物的工作是我们中心的一项重大进展，并且正在进行更多的随机前瞻性研究以确定移植后最佳的抗真菌预防措施。杜克大学及其他地方正在进行的临床和基础研究应继续推动临床移植领域的发展，并最终为肺移植受者带来更理想的长期结果。
